HealthQuill Articles by: HealthQuill
Gilead Sciences and Kymera Therapeutics have signed a $750 million license agreement to develop a new cancer medicine to treat breast cancer and other solid tumours. 
Drugs Health Pharma

Gilead, Kymera Therapeutics in $750m pact to make new cancer drug

HQ Team June 25, 2025: Gilead Sciences Inc. and Kymera Therapeutics have signed a $750 million license agreement to develop a new cancer

Read More
People who rely on artificial intelligence chatbots had reduced levels of brain activity and produced “soulless” essays in an MIT study.
Health Medical Research

Large language models reduce brain activity, produce ‘soulless’ essays: MIT

HQ Team July 25, 2025: People who rely on artificial intelligence chatbots had reduced levels of brain activity and produced “soulless” essays in

Read More
Illumina, Inc. will acquire California-based SomaLogic, a company that is involved in identifying and quantifying proteins within a cell, for $425 million, according to a company statement.
Drugs Health Pharma

Illumina to acquire proteomics company SomaLogic in $425 million all cash deal

HQ Team June 23, 2025: Illumina, Inc. will acquire California-based SomaLogic, a company that is involved in identifying and quantifying proteins within a

Read More
Danish drugmaker Novo Nordisk will terminate its agreement with a US-based telehealth company, Hims & Hers Health Inc., to sell its weight-loss drug, Wegovy.
Drugs Health Medical

Novo terminates agreement with Hims & Hers to sell weight-loss drug

HQ Team June 23, 2025: Danish drugmaker Novo Nordisk will terminate its agreement with a US-based telehealth company, Hims & Hers Health Inc.,

Read More
US-based researchers at Northeastern University are trying to unravel how axolotls, a small salamander, a smooth-skinned amphibian that often lives in watery or damp places, regrow entire limbs and even organs, and may hold the secret to replicating it in humans.
Climate Health Research

Axolotls may hold the key to human organ regeneration: US researchers

 HQ Team June 23, 2025: US-based researchers at Northeastern University are trying to unravel how axolotls, a small salamander, a smooth-skinned amphibian that

Read More
Private corporations stand to profit from smartphone apps that track menstrual cycles as they provide a ‘gold mine’ for consumer profiling, collecting information on everything from exercise, diet and medication to sexual preferences, hormone levels and contraception use, according to a report.
Health Medical Research

‘Menstrual tracking data being used to control people’s reproductive lives’

HQ Team June 23, 2025: Private corporations stand to profit from smartphone apps that track menstrual cycles as they provide a ‘gold mine’

Read More
Novo Nordisk A/S’s data from a clinical trial of a weight-loss medicine, treating overweight and obese adult participants, showed patients lost about 23% of their body weight compared to a dummy group’s 2-3%.
Drugs Health Pharma

Novo Nordisk’s obesity drug CagriSema cuts weight by 23%

HQ Team June 22, 2025: Novo Nordisk A/S’s data from a clinical trial of a weight-loss medicine, treating overweight and obese adult participants,

Read More
Madrigal Pharmaceuticals EU Limited's therapy to treat adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) got a conditional marketing authorisation in the European Union. 
Drugs Health Medical

Madrigal’s therapy to treat MASH in adults gets EU’s initial nod

HQ Team June 22, 2025: Madrigal Pharmaceuticals EU Limited’s therapy to treat adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) got a conditional marketing

Read More
Supernus Pharmaceuticals, Inc. will acquire Sage Therapeutics, Inc. for a total consideration of up to $795 million, to gain access to a medicine to treat postpartum depression.
Drugs Health Pharma

Supernus Pharma to acquire Sage Therapeutics for $795 million all cash

HQ Team June 22, 2025: Supernus Pharmaceuticals, Inc. will acquire Sage Therapeutics, Inc. for a total consideration of up to $795 million, as

Read More
Novo Nordisk’s experimental weight loss medicine amycretin helped overweight and obese adults lose up to 24% of their weight in a small study, according to a company statement.
Drugs Health Pharma

Novo Nordisk’s amycretin drug helps obese adults lose 24% weight

HQ Team June 21, 2025: Novo Nordisk’s experimental weight loss medicine amycretin helped overweight and obese adults lose up to 24% of their

Read More